Commentary: non-HIV hypotheses must be studied more carefully Peter 
Duesberg
Patients with haemophilia treated with commercial factor VIII and confirm the zidovudine hypothesis, as "all nine HIV positive patients with AIDS received zidovudine" in addition to the "toxic" pentamidine,'0 co-trimoxazole, and fluconazole.'
The foreign protein hypothesis predicts that AIDS in patients with haemophilia can be prevented if not cured by using factor VIII that is free of foreign protein. Sabin et al endorse this: "These concentrates seem to preserve the immune system. . . ." Indeed, not only were the immune systems of HIV "positive haemophilic patients treated with pure factor VIII and no zidovudine "preserved" but their T cells increased by up to a quarter over three years-despite the presence of the hypothetical T cell killer HIV." 12 
Conclusion
The foreign protein-zidovudine hypothesis provides biochemically plausible candidates for pathogenicitythat is, large amounts of foreign proteins transfused over decades and DNA chain terminators prescribed indefinitely such as zidovudine. With a daily dose of 500 mg zidovudine a person receives 2x 1020 molecules, or 2 x 106 for every human cell, every day for the rest of his life. By contrast, after 11 years of research the HIV hypothesis has yet to identify a single molecule that could be pathogenic. ' Observational studies often show that patients given zidovudine have a worse prognosis than untreated patients.7 Patients receiving zidovudine are selectively treated because they are ill. The interpretation of findings from these studies should not therefore be that zidovudine increases the risk of AIDS. Of the nine patients developing AIDS in our study, seven received zidovudine only after an initial AIDS diagnosis when immunological deterioration had already occurred. There is no possibility, therefore, that either BMJ VOLUME 312 27jANuARY 1996
